Skip to content
Mesothelioma.net
phone iconCall1-800-692-8608 chat icon Chat 24/7 Live Chat
Menu
  • Malignant Mesothelioma
    • About Mesothelioma
      • How to Survive Mesothelioma
      • 100 Questions & Answers about Mesothelioma (Free Book)
      • Symptoms
      • Diagnosis
      • Prognosis
      • Life Expectancy
    • Types
      • Pleural
      • Peritoneal
      • Epithelioid
      • Sarcomatoid
      • Biphasic
    • Stages
      • Stage 1
      • Stage 2
      • Stage 3
      • Stage 4
    • Additional Information
      • Causes
      • Asbestos and Its Dangers
      • Facts
      • Support
      • Financial Compensation
      • FREE Mesothelioma Packet
  • Treatment
    • Treatment Options
      • Surgery
      • Chemotherapy
      • Radiation Therapy
      • Multimodal Therapy
      • Medications
      • Palliative Treatment
    • Find Top Doctors
      • Doctors
      • Treatment Centers
      • Treatment & Doctors Near You
      • New Treatments
      • Care Providers
      • Clinical Trials
      • Costs
  • Asbestos Trusts
  • Compensation
  • Veteran Assistance
    • Mesothelioma and Veterans
      • VA Claims for Mesothelioma
      • Vietnam Veterans
    • Military Branches and Asbestos
      • Navy Veterans
      • Navy Ships
      • Marine Corps Veterans
      • Army Veterans
      • Air Force Veterans
      • U.S. Coast Guard
  • Surviving Mesothelioma
  • About Us / Contact
  • Home
  • ›
  • Malignant Mesothelioma
  • ›
  • Latest Research
Page Updated: June 27, 2022

Latest Mesothelioma Research

Anne Courtney Page Medically Reviewed and Edited by Anne Courtney, AOCNP, DNP

FREE Mesothelioma Packet

Fact Checked

This page has been fact-checked by a Doctor of nursing practice specializing in Oncology and has experience working with mesothelioma patients.

FREE Mesothelioma Packet

Sources of information are listed at the bottom of the article. We make every attempt to keep our information accurate and up-to-date. 

Please Contact Us with any questions or comments.

The latest mesothelioma research includes new immunotherapy drugs, combinations of immunotherapy and chemotherapy, and novel ways of using chemotherapy drugs. Researchers are also working on new diagnostic techniques and genetic studies of mutations that may cause mesothelioma.

FREE Mesothelioma Packet

FDA Approves Immunotherapy

In 2020, the Food and Drug Administration approved the first new drugs for mesothelioma in 15 years. Based on the CheckMate 743 clinical trials, the new therapy is a combination of two immunotherapy drugs:[1][2]

  • Nivolumab – A checkpoint inhibitor, it blocks signals from the tumor trying to tell immune system T-cells to leave cancer cells alone
  • Ipilimumab – A monoclonal antibody, it activates the patient’s immune system by going after a protein receptor that normally slow sit down

The study included more than 600 patients with pleural mesothelioma, half assigned to platinum-based chemotherapy (a standard mesothelioma treatment) and half to immunotherapy. The group receiving CheckMate 743 had significantly longer two-year survival times as compared to the traditional therapy, 40.8% compared to 27.0%.[1]

Combining Immunotherapy and Chemotherapy

Chemotherapy is a standard treatment for mesothelioma, while immunotherapy is more experimental. Research reported just a few months ago indicates that a combination of the two could be a more effective treatment strategy.[3]

Researchers worked with 55 patients with inoperable pleural mesothelioma to provide this first-line treatment:[3]

  • Immunotherapy drug durvalumab
  • Chemotherapy drug cisplatin
  • Chemotherapy drug pemetrexed

The combination was novel, and the results promising. The average survival time went up from 12 months with just chemotherapy to 20.4 months. This was the first time survival rates went above 20 months for patients with inoperable mesothelioma.[3]

The clinical trials using these drugs led to approval by the FDA. This combination is the first immunotherapy approved to treat pleural mesothelioma. Treatment for peritoneal mesothelioma is still in the clinical trial phase.[3]

Transarterial Chemoperfusion

Another novel treatment recently tested with pleural mesothelioma patients, transarterial chemoperfusion gave patients extended life expectancy in a clinical trial. The trial included 27 patients who had been treated for pleural mesothelioma but experienced disease progression. The novel treatment extended survival, improved quality of life, and caused only a few minor side effects.[4]

Patients receive traditional chemotherapy intravenously; it circulates throughout the body. For this novel treatment, clinicians injected a mix of three chemotherapy drugs directly into the artery that supplies blood to the pleural tissue.[4]

This more targeted administration of drugs not only concentrated them on the cancer cells but also spared many healthy cells. This explains the minimal side effects.[4]

Tazemetostat – Protein Inhibitor

Several recent studies have shown the effectiveness and safety of the new drug tazemetostat in patients with mesothelioma. The drug targets an enzyme, known as EZH2. This enzyme normally blocks genes that suppress tumor growth.[5]

More than half of mesothelioma patients have a genetic mutation in BAP1, the gene that suppresses tumors. The mutation causes higher expression of EZH2, leading to rapid cancer growth. Tazemetostat is particularly effective in these patients.[5]

In one of the studies, 74 patients with recurring mesothelioma and with the right gene mutation took tazemetostat twice a day with few side effects. The drug improved the disease control rate, keeping it stable or at least showing a positive response.[5]

Tumor Treating Fields

The FDA approved this new therapy for treating mesothelioma in 2019. Known as NovoTTF-100L, the Novocure system proved in clinical trials to provide pleural mesothelioma patients with a median survival time of over 18 months.[6]

The approved therapy uses the system along with chemotherapy as a first-line treatment. Tumor treating fields uses applied electrical fields to disrupt cell division, kill cancer cells, and slow tumor growth.[6]

Anti-Angiogenic Drugs

Anti-angiogenic agents block the development of new blood vessels. Tumors need these blood vessels to supply nutrients for cell growth. Blocking them essentially starves the tumor, resulting in cell death.[7]

Bevacizumab combined with chemotherapy has shown promising results in clinical trials. It seems to extend the overall survival time for patients with mesothelioma. Researchers are testing other anti-angiogenic drugs with mixed results.[7]

Increased Funding for Genetic Mesothelioma Research

The BAP1 gene is of particular interest to mesothelioma researchers because of the role its mutation plays in the development of the disease. People with a mutation in BAP1 are at a greater risk of being diagnosed with this cancer.[8]

The National Institutes of Health recently awarded a research team at the University of Hawaii Cancer Center, over $2.5 million to keep studying BAP1 and mesothelioma. So far the researchers know that the mutation increases cancer risk, but it also tends to trigger less aggressive cancers. They hope to uncover more novel treatments targeting BAP1 that save the lives of mesothelioma patients.[8]

Inhalable Gene Therapy

A very recent study reported on the development of a novel treatment for non-small cell lung cancer and pleural mesothelioma.[9]

Researchers created a minimally invasive tumor suppressor gene drug. It uses an inhalant powder to deliver the drugs directly to the lungs and chest cavity. If successful, this could be a treatment that patients self-administer.[9]

It has not yet been tested in human subjects, but studies with cell lines show promise. The drugs decreased cell proliferation in lines for both lung cancer and mesothelioma.[9]

Liquid Biopsy for Mesothelioma Diagnosis

Diagnosing mesothelioma in a timely and accurate way continues to be a challenge. An earlier diagnosis gives patients more treatment options and better survival times, so researchers continue to look for better ways to detect this cancer.[10]

Cellular Analytics, a company based in Canada, recently released CytoFind, a new type of liquid biopsy test for mesothelioma. It is based on technology that separates individual cancer cells from a patient’s bloodstream.[10]

The test may be able to detect precancerous cells in the blood, providing a much earlier diagnosis than has ever been possible. The test can also look at responses to immunotherapy drugs, identifying which treatments will be most effective for individual patients.[10]

These and other studies are ongoing, bringing hope to mesothelioma patients. While the cancer is still considered largely incurable, these kinds of novel treatments and diagnostics keep pushing the boundaries of what is possible.

Get Your FREE Mesothelioma Packet

Page Medically Reviewed and Edited by Anne Courtney, AOCNP, DNP

Anne Courtney

Anne Courtney has a Doctor of Nursing Practice degree and is an Advanced Oncology Certified Nurse Practitioner. She has years of oncology experience working with patients with malignant mesothelioma, as well as other types of cancer. Dr. Courtney currently works at University of Texas LIVESTRONG Cancer Institutes.

Connect with Doctor of Nursing Practice Anne Courtney
References
  1. Eurekalert. (2020, August 8). CheckMate 743 Shows That Dual Immunotherapy, Nivolumab + Ipilimumab IMproves Overall Survival for Patients with Previously Untreated Mesothelioma.
    Retrieved from: https://www.eurekalert.org/pub_releases/2020-08/iaft-c7s080520.php
  2. Bristol Myers Squibb. (2020, October 2). U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) as the First and Only Immunotherapy Treatment for Previously Untreated Unresectable Malignant Pleural Mesothelioma.
    Retrieved from: https://news.bms.com/news/details/2020/U.S.-Food-and-Drug-Administration-Approves-Opdivo-nivolumab–Yervoy-ipilimumab-as-the-First-and-Only-Immunotherapy-Treatment-for-Previously-Untreated-Unresectable-Malignant-Pleural-Mesothelioma/default.aspx
  3. Science Daily. (2020, June 11). Chemotherapy/Immunotherapy Combo Shows Promise for First-Line Treatment of Mesothelioma.
    Retrieved from: https://www.sciencedaily.com/releases/2020/06/200611152457.htm
  4. Science Daily. (2020, June 15). Novel Treatment for Mesothelioma Shows Promise for Patients.
    Retrieved from: https://www.sciencedaily.com/releases/2020/06/200615092733.htm
  5. Zauderer, M.G., Szlosarek, P.W., Le Moulec, S., Popat, S., Taylor, P., Planchard, D., Sherpereel, A., Jahan, T.M., Koczywas, M., Forster, M., Cameron, R.B., Peikert, T., Argon, E.K., Michaud, N., Yang, J., Kansra, V., and Fennell, D.A. (2020). Safety and Efficacy of Tazemetostat, an Enhancer of Zeste-Homolog 2 Inhibitor, in Patients with Relapsed or Refractory Malignant Mesothelioma. J. Clin. Oncol. 38(15).
    Retrieved from: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.9058
  6. Novocure. (2019, May 23). FDA Approves the NovoTTF-100L™ System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma.
    Retrieved from: https://www.novocure.com/fda-approves-the-novottf-100ltm-system-in-combination-with-chemotherapy-for-the-treatment-of-malignant-pleural-mesothelioma/
  7. Cantini, L., Hassan, R., Sterman, D.H., and Aerts, J.G.J.V. (2020, March 12). Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading? Front. Oncol. https://doi.org/10.3389/fonc.2020.00343.
    Retrieved from: https://www.frontiersin.org/articles/10.3389/fonc.2020.00343/full
  8. University of Hawaii. (2019, December 17). Cancer-Related Gene Research Leads to $2.6M Grant.
    Retrieved from: http://www.uhm.hawaii.edu/news/article.php?aId=10356
  9. Ichikawa, M., Muramatsu, N., Matsunaga, W., Ishikawa, T., Okuda, T., Okamoto, H., and Gotoh, A. (2022). Effects of Inhalable Gene Transfection as a Novel Gene Therapy for Non-Small Cell Lung Cancer and Malignant Pleural Mesothelioma. Scientific Reports. 12(8634), https://doi.org/10.1038/s41598-022-12624-4.
    Retrieved from: https://www.nature.com/articles/s41598-022-12624-4
  10. Gilmore, J. (2020, January 7). Circulating Tumor Cell Collection, Analysis Methods Make Headway in 2019. GenomeWeb.
    Retrieved from: https://cbef8283-f5f6-4205-8112-78dd87c2d4e6.filesusr.com/ugd/98ff36_48853a0f401c4c979d656daabbc94dbb.pdf
View All References

Site Navigation

Home
Malignant Mesothelioma
How to Survive Mesothelioma
100 Questions & Answers about Mesothelioma (Free Book)
Surviving Mesothelioma - Beating the Odds (Free Book)
FREE Mesothelioma Packet
Symptoms
Shortness of Breath
Cough
Night Sweats and Fever
Weight Loss
Pain
Difficulty Swallowing
Fatigue and Muscle Weakness
Gastrointestinal Complications
Diagnosis
Pathology
Staging
Stage 1
Stage 2
Stage 3
Stage 4
Metastasis and Progression
Brain Metastasis
Biopsy
miRview Test
Imaging
Fine Needle Aspiration Biopsy in Mesothelioma
Biomarkers and Blood Tests
Calretinin
Prognosis
Remission
Recurrence
Death Rate
Life Expectancy
Search for a Mesothelioma Cure
Types
Pleural
Peritoneal
Epithelioid
Sarcomatoid
Biphasic
Pericardial
Testicular
Cell Types
Rare Subtypes of Mesothelioma
Deciduoid
Desmoplastic
Heterologous
Lymphohistiocytoid
Well-Differentiated Papillary
Tubulopapillary
Small Cell
Benign
Adenomatoid
Cystic
Unresectable
Localized
Idiopathic
Omental
Causes
Risk Factors
Latest Research
Genetic Components
Incidence
Latency Period
Mesothelioma Tumor
Health Insurance Coverage
Related Conditions
Immunodeficiency Disorders
Cholangiocarcinoma
Atelectasis
Pleural Plaques
Pleural Thickening
Pleural Effusion
Peritoneal Effusion (Ascites)
Mesothelial Hyperplasia and Proliferation
Pleuritis and Pleurisy
COPD
Anemia
Breast Cancer
Prevention
Complications
Misdiagnosis
Mesothelioma Commercial
Talcum Baby Powder
Lawyer
Lawsuits
Class Action Lawsuits
Settlements
Simian Virus 40
Differences From Other Cancers
Lung Cancer
Women
Children and Young Adults
Unknown Asbestos Exposure
Mesothelioma Without Asbestos
Cause of Death
Facts 
History
Awareness
Government and Research
National Mesothelioma Virtual Bank
Support
What to Expect
Living with Mesothelioma
Help a Loved One
Wrong and Right Things to Say
Caregivers
Financial Tips
Faith
Nutrition and Lifestyle
Intimacy
Mesothelioma and Fertility in Men
Fertility in Women with Mesothelioma
Emotional Health
COVID-19
Assisted Living
Hospice Care
Dying from Mesothelioma
Mourning
Coping Guide for Children
End-of-Life Decisions
Mesothelioma Awareness Day
Compensation for Victims
Lawyer
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington D.C.
Washington
West Virginia
Wisconsin
Wyoming
Lawsuit
Settlements
Statute of Limitations
Treatment
Surgery
Side Effects
Pneumonectomy
Extrapleural Pneumonectomy
Lobectomy
Pleurectomy/Decortication
Post Op Care
Pleurectomy/Decortication vs. Extrapleural Pneumonectomy
Peritonectomy/Cytoreductive Surgery
Thoracotomy
Thoracoscopy
Pericardiectomy
Wedge Resection
Pleurodesis
Pericardiocentesis
Prosthetics
Paracentesis
Thoracentesis
Chemotherapy
Side Effects
Heated Intraperitoneal
Radiation Therapy
Side Effects
Intensity-Modulated
Brachytherapy
Proton Therapy
Image-Guided
External Beam
Three-Dimensional
Multimodal Therapy
New Treatments
SMART Protocol
Gene Therapy
Suicide Gene Therapy
Tumor-Based p53 Therapy
Cryotherapy for Mesothelioma
Tumor Treating Fields
MicroRNA
Palliative Treatment
Osteopathic
Doctors
Treatment Centers
Treatment & Doctors Near You
Mesothelioma Experts
Medications
Alimta (pemetrexed)
Adriamycin (doxorubicin)
Avastin (bevacizumab)
Cytoxan (cyclophosphamide)
Gemzar (gemcitabine)
Keytruda (Pembrolizumab)
Mitomycin
Navelbine (vinorelbine)
Opdivo (nivolumab) and Yervoy (ipilimumab)
Paraplatin (carboplatin)
Platinol (cisplatin)
Rheumatrex (methotrexate)
Sutent (sunitinib)
Taxol (paclitaxel)
Medical Marijuana
Care Providers
Clinical Trials
Anetumab Ravtansine
Atezolizumab
Chimeric Antigen Receptor (CAR) T-Cell
Durvalumab
Immunotoxin
Interferon Alfa-2b
Onconase (Ranpirnase)
VISTA Protein
Costs
Immunotherapy
Nanotechnology
Hyperbaric Oxygen Therapy
Home Medical Equipment
HMGB1 Secretion
Photodynamic Therapy
Targeted Therapies
Apoptosis
Stem Cells
Lung Transplantation
Body-Based Therapies
Alternative Therapies
Paul Kraus’s Method
Doctors and Treatment in Canada
Asbestos Trusts
Veterans
VA Claims for Mesothelioma
Vietnam Veterans
Military Branches and Asbestos
Navy Veterans
Navy Ships
Aircraft Carriers
Battleships
Destroyers
Asbestos on Navy Cruisers
Submarines
Amphibious Ships
Minesweepers
Auxiliary Ships
Marine Corps Veterans
Army Veterans
Air Force Veterans
U.S. Coast Guard
Asbestos
Occupational Exposure
Construction Workers
Shipyard Workers
Ship Repair
Steel Mill Workers
Industrial Workers
Boiler Workers
Power Plant Workers
Firefighters
Automotive Workers
Roofers
Oil Refineries
Mining
Transportation Industry
Machine Operators
Farmers and Agricultural Workers
Migrant Workers
Electrical Wiring
Labor Unions
Prisons
Chimneys, Furnaces, and Wood Stoves
Fiberglass Connection to Mesothelioma
Home Remodeling
School Buildings, Teachers
For Tech Students
Cancer
Lung Cancer
Pleural Based Cancers
Ovarian Cancer
Ovarian Cancer Lawsuits
Companies That Used Asbestos
Awareness and Education
Types of Asbestos & Mesothelioma Risk
Asbestosis
Interstitial Lung Disease
Smoking
Asbestos Ingestion
Exposure in a Natural Disaster
Ban Asbestos
Libby, Montana
Recycling Asbestos
Asbestos Detection
Legal Information by State
Canada
Mexico
United Kingdom
Australia
  • Malignant Mesothelioma
    • Treatment
    • Asbestos Trusts
  • Compensation
    • Veteran Assistance
    • Surviving Mesothelioma
  • FREE Mesothelioma Packet
    • Mesothelioma News
    • About Us / Contact
  • Privacy Policy
    • Disclaimer
    • Editorial Guidelines and Standards
This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.
The information provided by Mesothelioma.net is not a substitute for professional medical advice, diagnosis or treatment.

Mesothelioma.net

5430 LBJ Freeway Suite 1200
Dallas, Texas 75240

Serving mesothelioma victims nationwide

1-800-692-8608

  • facebook
  • twitter
© 2022 Mesothelioma.net